{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:06:35Z","timestamp":1753877195320,"version":"3.41.2"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To establish a nomogram model for predicting chemotherapy-induced nausea and vomiting (CINV) in patients with gynecological malignancies based on relevant risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included patients with gynecological malignancies hospitalized in the oncology department of Affiliated People\u2019s Hospital of Jiangsu University between February 2020 and October 2021. Patients were divided into a training set (between February 2020 and December 2020) and a validation set (between January 2021 and October 2021). Basic and clinical characteristics were collected and analyzed by univariate and multivariate logistic regression. A nomogram was constructed and assessed with the receiver operating characteristic curve (ROC). We have also conducted an external validation using data from 297 patients with gynecological malignancies admitted to two oncology wards at our hospital (140 patients from Ward 1 and 157 patients from Ward 2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study comprised 148 patients in the training set and 148 in the validation set. Multivariate analysis revealed age\u00a0&amp;lt;60\u00a0years (OR (Odds Ratio)\u00a0=\u00a04.001, 95% CI (Confidence interval) 1.349\u201311.872, P\u00a0=\u00a00.012), presence of motion sickness (OR\u00a0=\u00a03.841, 95% CI 1.200\u201312.296, P\u00a0=\u00a00.023), history of pregnancy-related vomiting (OR\u00a0=\u00a04.067, 95% CI 1.203\u201313.751, P\u00a0=\u00a00.024), and the use of moderate\/high emetogenic chemotherapy drugs (OR\u00a0=\u00a010.299, 95% CI 2.858\u201337.115, P\u00a0&amp;lt;\u00a00.001) as independent risk factors for CINV. These factors were incorporated into a nomogram, which exhibited an area under the ROC (AUC) of 0.844, with a sensitivity of 81.4% and specificity of 80.0% at the optimal cut-off point of 159.48. The AUC for validation was 0.945, with sensitivity and specificity of 91.5% and 87.1% at the optimal cut-off point of 159.48, respectively. The external validation results showed an AUC of 0.704 (95% CI: 0.648\u20130.755), with a sensitivity of 93.33% and specificity of 48.15% (P\u00a0=\u00a00.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The developed nomogram, incorporating age, moderate\/high emetogenic chemotherapy drugs, motion sickness, and pregnancy vomiting history, showed good discrimination for CINV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf042","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:59:36Z","timestamp":1741604376000},"page":"736-742","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a nomogram model for predicting CINV in patients with gynecological malignancies"],"prefix":"10.1093","volume":"55","author":[{"given":"Xuelian","family":"Zhou","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Kangda College of Nanjing Medical University , 6 zhenhua East Rd., Lianyungang 222000 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-9515","authenticated-orcid":false,"given":"Tingting","family":"Fan","sequence":"additional","affiliation":[{"name":"Oncology Department, Affiliated People\u2019s Hospital of Jiangsu University , 8 Dianli Rd., Zhenjiang 212002 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2025070702414770200_ref1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S1470-2045(22)00386-2","article-title":"Coordinated efforts to harmonise gynaecological cancer care","volume":"23","author":"Costa","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025070702414770200_ref2","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.ctrv.2022.102396","article-title":"GCIG-consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the gynecologic cancer intergroup (GCIG) symptom benefit committee","volume":"107","author":"Woopen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2025070702414770200_ref3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1177\/1054773817704586","article-title":"Chemotherapy-induced nausea and vomiting: Incidence and Management in Jordan","volume":"27","author":"Al Qadire","year":"2018","journal-title":"Clin Nurs Res"},{"key":"2025070702414770200_ref4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2147\/TCRM.S133820","article-title":"Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: A prospective observational study","volume":"13","author":"Vazin","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2025070702414770200_ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/apt.16386","article-title":"Review article: The evolution of endpoint assessments for chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting-a perspective from the US Food and Drug Administration","volume":"54","author":"Gabby","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025070702414770200_ref6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025070702414770200_ref7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","article-title":"Prognostic factors for chemotherapy induced nausea and vomiting","volume":"722","author":"Warr","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2025070702414770200_ref8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00520-020-05484-z","article-title":"A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation","volume":"29","author":"Armbruster","year":"2021","journal-title":"Support Care Cancer"},{"key":"2025070702414770200_ref9","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025070702414770200_ref10","doi-asserted-by":"publisher","first-page":"110804","DOI":"10.1016\/j.jpsychores.2022.110804","article-title":"The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"157","author":"Jung","year":"2022","journal-title":"J Psychosom Res"},{"key":"2025070702414770200_ref11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cac2.12397","article-title":"Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: Results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin","volume":"43","author":"Zhao","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"2025070702414770200_ref12","doi-asserted-by":"publisher","first-page":"18306","DOI":"10.1002\/cam4.6428","article-title":"A deep learning-based interpretable decision tool for predicting high risk of chemotherapy-induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"2025070702414770200_ref13","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/cncr.1984.53.s10.2267","article-title":"Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research","volume":"53","author":"Morrow","year":"1984","journal-title":"Cancer"},{"key":"2025070702414770200_ref14","doi-asserted-by":"publisher","first-page":"e047258","DOI":"10.1136\/bmjopen-2020-047258","article-title":"Global epidemiology of hip fractures: A study protocol using a common analytical platform among multiple countries","volume":"11","author":"Sing","year":"2021","journal-title":"BMJ Open"},{"key":"2025070702414770200_ref15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025070702414770200_ref16","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ (Clinical research ed)"},{"key":"2025070702414770200_ref17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"2025070702414770200_ref18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"key":"2025070702414770200_ref19","doi-asserted-by":"publisher","first-page":"e29094","DOI":"10.7759\/cureus.29094","article-title":"The effectiveness of an oral fixed-dose combination of Netupitant and Palonosetron (NEPA) in patients with multiple risk factors for chemotherapy-induced nausea and vomiting: A Multicenter, observational Indian study","volume":"14","author":"Vaswani","year":"2022","journal-title":"Cureus"},{"key":"2025070702414770200_ref20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.critrevonc.2011.09.005","article-title":"The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies","volume":"83","author":"Schwartzberg","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025070702414770200_ref21","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s00520-016-3080-y","article-title":"Chemotherapy-induced nausea and vomiting: Incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (alliance)","volume":"24","author":"Kottschade","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025070702414770200_ref22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2019.7526","article-title":"What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly Emetogenic chemotherapy","volume":"18","author":"Roeland","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025070702414770200_ref23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","article-title":"International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice","volume":"722","author":"Jordan","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2025070702414770200_ref24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00540-020-02781-z","article-title":"Effects of menstrual cycle on nausea and vomiting after general anesthesia","volume":"34","author":"Zou","year":"2020","journal-title":"J Anesth"},{"key":"2025070702414770200_ref25","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2025070702414770200_ref26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","article-title":"Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: A prospective registration study by the CINV study group of Japan","volume":"18","author":"Tsuji","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"2025070702414770200_ref27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00520-015-2882-7","article-title":"How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study","volume":"24","author":"Vanbockstael","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025070702414770200_ref28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CE.S203634","article-title":"Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A short review on the role of Netupitant-Palonosetron (NEPA)","volume":"15","author":"Lorusso","year":"2020","journal-title":"Core Evid"},{"key":"2025070702414770200_ref29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40360-020-00445-y","article-title":"5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: A multicenter, prospective, observational study","volume":"21","author":"Matsui","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025070702414770200_ref30","doi-asserted-by":"publisher","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: A randomized clinical trial","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025070702414770200_ref31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/00000542-199207000-00023","article-title":"Postoperative nausea and vomiting. Its etiology, treatment, and prevention","volume":"77","author":"Watcha","year":"1992","journal-title":"Anesthesiology"},{"key":"2025070702414770200_ref32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1620\/tjem.254.111","article-title":"Nomogram for predicting chemotherapy-induced nausea and vomiting for breast cancer patients","volume":"254","author":"Huang","year":"2021","journal-title":"Tohoku J Exp Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/7\/736\/62365389\/hyaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/7\/736\/62365389\/hyaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:41:53Z","timestamp":1751870513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/7\/736\/8068403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,10]]},"published-print":{"date-parts":[[2025,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf042","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,10]]}}}